Teva Pharmaceutical Industries (TEVA) Profit After Tax (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Profit After Tax for 18 consecutive years, with -$576.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Profit After Tax fell 303.53% year-over-year to -$576.0 million; the trailing twelve-month figure through Jun 2026 stood at $708.0 million (up 438.76% YoY), and the FY2025 full-year result was $1.4 billion, up 172.38% from the prior year.
• Profit After Tax declined to -$576.0 million in Q2 2026 per TEVA's latest filing, from $369.0 million in the prior quarter.
• Across five years, Profit After Tax topped out at $481.0 million in Q4 2025 and bottomed at -$1.3 billion in Q4 2022.
• Historically, Profit After Tax has averaged -$217.4 million across 5 years, with a median of -$264.0 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Profit After Tax slumped 1236.9% in 2022, then surged 274.91% in 2025.
• Over 5 years, Profit After Tax stood at -$1.3 billion in 2022, then jumped by 134.88% to $465.0 million in 2023, then tumbled by 159.14% to -$275.0 million in 2024, then soared by 274.91% to $481.0 million in 2025, then tumbled by 219.75% to -$576.0 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$576.0 million, $369.0 million, and $481.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.